Display omitted
Mesenchymal stem cells (MSCs) play important roles in therapeutic applications by regulating immune responses.
We investigated the safety and efficacy of allogenic human bone ...marrow–derived clonal MSCs (hcMSCs) in subjects with moderate to severe atopic dermatitis (AD).
The study included a phase 1 open-label trial followed by a phase 2 randomized, double-blind, placebo-controlled trial that involved 72 subjects with moderate to severe AD.
In phase 1, intravenous administration of hcMSCs at 2 doses (1 × 106 and 5 × 105 cells/kg) was safe and well tolerated in 20 subjects. Because there was no difference between the 2 dosage groups (P = .9), it was decided to administer low-dose hcMSCs only for phase 2. In phase 2, subjects receiving 3 weekly intravenous infusions of hcMSCs at 5 × 105 cells/kg showed a higher proportion of an Eczema Area and Severity Index (EASI)-50 response at week 12 compared to the placebo group (P = .038). The differences between groups in the Dermatology Life Quality Index and pruritus numeric rating scale scores were not statistically significant. Most adverse events were mild or moderate and resolved by the end of the study period.
The hcMSC treatment resulted in a significantly higher rate of EASI-50 at 12 weeks compared to the control group in subjects with moderate to severe AD. The safety profile of hcMSC treatment was acceptable. Further larger-scale studies are necessary to confirm these preliminary findings.
Background
The development of dermatitis on face and neck, which was not described in phase 3 clinical trials, has been reported in the literature in patients treated with dupilumab. Little is known ...regarding the causes or defining features of the facial dermatitis.
Objectives
We conducted surveys of consecutive patients with AD on dupilumab to describe its clinical features, morphology and aetiology.
Methods
A multi‐centre prospective cohort study was conducted from 1 January 2020, to 31 December 31 2020. A total of 162 patients under dupilumab treatment were asked to complete a questionnaire and patients were evaluated by dermatologists.
Results
Of all 162 patients, 137 (84.6%) patients reported pre‐existing facial dermatitis prior to dupilumab therapy. One hundred and twenty‐one (88.3%) patients with pre‐existing facial dermatitis reported improvement of their facial dermatitis with dupilumab therapy, nine (6.6%) patients reported no change after the treatment and seven (4.3%) patients of them got worse after the treatment (exacerbation group). Of 25 patients who reported no pre‐existing active facial dermatitis, six (24%) patients reported new‐onset facial erythema after the starting dupilumab therapy (new‐onset group). A large proportion of the patients in both the exacerbation (86%) and new‐onset groups (67%) had a history of facial TCS use. Both groups showed similar clinical manifestations and distribution with few differences.
Conclusions
The vast majority of patients treated with dupilumab in academic institutions from Korea and the United States experienced improvement in their facial dermatitis with dupilumab therapy. A small proportion of patients had new onset and exacerbation. Although the mechanisms of this adverse event remain unclear, steroid withdrawal should be considered as a diagnosis of the erythema in some patients.
Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominantly inherited disorder characterized by multiple trichodiscomas, fibrofolliculomas, and acrocordons. There is also an increased risk of ...developing renal neoplasms and lung cysts/spontaneous pneumothorax. We present a 43-year-old man with multiple, 2~4 mm sized, dome-shaped, and skin-colored papules on his cheek and neck. On the basis of clinical finding and histopathologic examination on the cheek lesion, it was diagnosed as multiple trichodiscomas. Subsequently, molecular analysis revealed a mutation in the folliculin gene. We report a rare case of BHDS with a proved gene mutation.
Although there are several available management strategies for treatment of both acute pain of herpes zoster (HZ) and postherpetic neuralgia (PHN), it is difficult to treat them adequately.
The aim ...of this study was to evaluate the efficacy of intravenously administrated vitamin C on acute pain and its preventive effects on PHN in patients with HZ.
Between September 2011 and May 2013 eighty-seven patients who were admitted for HZ were assessed according to age, sex, underlying diseases, duration of pain and skin lesion, dermatomal distribution, and PHN. It was a randomized controlled study, in which 87 patients were randomly allocated into the ascorbic acid group and control group. Each patient received normal saline infusion with or without 5 g of ascorbic acid on days 1, 3, and 5 then answered questionnaires that included side effects and pain severity using visual analogue scale on days 1, 2, 3, 4, and 5. After discharge, the severity of pain was obtained at out-patient clinic or by telephone on weeks 2, 4, 8, and 16.
There was no differences in severity of pain on patients' age, sex, underlying diseases, duration of pain and skin lesion and dermatomal distribution between two groups (
>0.05). Since 8th week, pain score in ascorbic acid treatment group was significantly lower than control group (
<0.05). The incidence of PHN was significantly lower in the treatment group compared to control group (
=0.014). The changes of overall pain score was significantly different between the two groups (
<0.05).
Intravenously administered ascorbic acid did not relieve acute HZ pain; but is effective for reducing the incidence of PHN.
TCTAP C-027 Measure Twice, Cut Once Cheng, Chi Na; Mak, Wai Lun; Chan, Tsz Ho ...
Journal of the American College of Cardiology,
04/2024, Letnik:
83, Številka:
16
Journal Article
PDF
